B. Riley Raises Price Target on LuxExperience to $14
Analyst firm B. Riley increased its price target for LuxExperience from $13 to $14 while maintaining a Buy rating.
Stocks · News reference
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst firm B. Riley increased its price target for LuxExperience from $13 to $14 while maintaining a Buy rating.
Bullish (BLSH) reported Q3 2026 earnings of $0.12 per share, beating consensus estimates of $0.08 and representing a 50% earnings surprise. Revenue of $84.4 million also exceeded expectations by 6.5%. However, the stock has declined 49.1% year-to-date compared to the S&P 500's 7.2% gain. With mixed estimate revisions, Bullish received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will be featured in approximately 100 abstracts at the 68th Annual Meeting of the American Society of Hematology (ASH).
Casey's General Stores, Inc. will release its second quarter 2027 financial results after the market closes on December 8, 2026, followed by a conference call on December 9, 2026.
LuxExperience reported strong Q1 FY27 financial results with net sales of €610.5 million and improved profitability, leading the company to raise its full-year growth and margin guidance.
Adaptogenics Health Corp. intends to raise up to $625,000 through a non-brokered private placement of units to fund its business initiatives.